BRISBANE, Calif., July 31 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced the appointment of John C. Hodgman to the position of Senior Vice President and Chief Financial Officer, effective August 14, 2006.
Hodgman has held senior leadership positions at a number of biotechnology and technology companies. In 2005, he was President and Chief Executive Officer of Aerogen, Inc. where he directed the company's merger with Nektar Corporation. From 1998 to 2005, he served as Chairman, President and CEO of Cygnus, Inc., where he led the commercialization of the first U.S. Food and Drug Administration-approved non-invasive continuous glucose monitoring system for patients with diabetes. Hodgman also served as Vice President of Finance, Chief Financial Officer of Cygnus from 1994 to 1998 in addition to serving as President of Cygnus' Diagnostic Division. He previously served as Vice President of Operations and Finance, Chief Financial Officer of Central Point Software, Inc.; Vice President of Finance and Administration, Chief Financial Officer of Ateq Corporation; and as a management consultant for Price Waterhouse. He currently serves on the boards of a number of publicly and privately held biotechnology and technology companies. Hodgman holds a B.S. from Brigham Young University and an M.B.A. from the University of Utah.
"John has an impressive track record that spans more than 25 years in the biotech and high-tech industries. His broad experience as a senior executive and director with several public companies will be very valuable to InterMune as we enter an important period in our Company's evolution," said Dan Welch, President and CEO of InterMune, Inc. "The InterMune executive team and staff look forward to working with John as we continue toward our goal of becoming a leader in the development of new medicines for pulmonary and hepatic diseases."
About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes two Phase III programs evaluating possible therapeutic candidates for treatment of patients with IPF: the INSPIRE trial is evaluating Actimmune(R) (interferon gamma-1b) and the CAPACITY program is evaluating pirfenidone. The hepatology portfolio includes the lead HCV protease inhibitor compound, ITMN-191, a second-generation HCV protease inhibitor program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.
Except for the historical information contained herein, this press release contains certain forward-looking statements that involve risks and uncertainties. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading 'Risk Factors' in InterMune's annual report on Form 10-K filed with the SEC on March 13, 2006 (the "Form 10-K") and updates included in the most recent Form 10-Q filed with the SEC on May 9, 2006 (the "Form 10-Q"), and other periodic reports filed with the SEC.
InterMune, Inc.CONTACT: investors, Investor Relations Dept, +1-415-466-2242, orir@intermune.com, or media, Pam Lord of Porter Novelli Life Sciences,+1-858-527-3494, plord@pnlifesciences.com, for InterMune, Inc.
Web site: http://www.intermune.com/
